Fast Track Given that FDA is fast tracking the evaluation of MCNA, they will want to try and get out in front of any or all possible pitfalls. But given the limited amount of data, the difficulty to run trials (since the standard of care was not available) and the desparate need I believe the drug will be approved, likley with many conditions and with the requirement to run a number of further studies.